Supplementation with Branched-chain Amino Acids Inhibits Azoxymethane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice

Masahito Shimizu,1 Yohei Shirakami,1 Junpei Iwasa,1 Makoto Shiraki,1 Yoichi Yasuda,1 Kazuya Hata,1 Yoshinobu Hirose,2 Hisashi Tsurumi,1 Takuji Tanaka,4 and Hisataka Moriwaki1

Abstract

Purpose: Obesity and related metabolic abnormalities, including insulin resistance and activation of the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis, are risk factors for colon cancer. Supplementation with branched-chain amino acids (BCAA) reduces the risk of liver cancer in cirrhotic patients who are obese, and this has been associated with an improvement of insulin resistance. The present study examined the effects of BCAA on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) mice that were obese and had hyperinsulinemia.

Experimental Design: Male db/db mice were given 4 weekly s.c. injections of AOM (15 mg/kg of body weight) and then they were fed a diet containing 3.0% BCAA or casein, a nitrogen content-matched control diet, for 7 weeks.

Results: Feeding with BCAA caused a significant reduction in the number of total aberrant crypt foci and β-catenin accumulated crypts, both of which are premalignant lesions of the colon, compared with the control diet–fed groups. BCAA supplementation caused a marked decrease in the expression of IGF-IR, the phosphorylated form of IGF-I, phosphorylated glycogen synthase kinase 3β, phosphorylated Akt, and cyclooxygenase-2 proteins on the colonic mucosa of AOM-treated mice. The serum levels of insulin, IGF-I, IGF-II, triglyceride, total cholesterol, and leptin were also decreased by supplementation with BCAA.

Conclusion: BCAA supplementation in diet improves insulin resistance and inhibits the activation of the IGF/IGF-IR axis, thereby preventing the development of colonic premalignancies in an obesity-related colon cancer model that was also associated with hyperlipidemia and hyperinsulinemia. BCAA, therefore, may be a useful chemoprevention modality for colon cancer in obese people.

Colorectal cancer (CRC) is a major health problem worldwide. Recent evidence indicates that the risk of CRC is elevated in patients with metabolic syndrome, also called insulin resistance syndrome, which is commonly associated with obesity and related metabolic abnormalities (1, 2). Obesity is the main determinant of insulin resistance and hyperinsulinemia, which is also a possible risk factor for CRC (3). CRC occurs more frequently in patients with diabetes mellitus, a condition associated with hyperinsulinemia (4, 5). Insulin has growth-promoting properties in CRC cells, and exogenous insulin injection stimulates the growth of CRC precursors in rodent models (6–8). In addition, elevated circulating levels of insulin causes alterations in the insulin-like growth factor (IGF)/IGF-I receptor (IGF-IR) axis, which is involved in the development and progression of CRC (9, 10). Therefore, increased insulin resistance and abnormalities in the IGF/IGF-IR axis might be a critical target to prevent the development of obesity-related malignancies, including CRC. For instance, (-)-epigallocatechin gallate, the major biologically active component of green tea, inhibited the development of colonic premalignant lesions in an obesity-related colon cancer that was associated with improvement in insulin resistance and inhibition of the IGF/IGF-IR axis (11).

Diet supplementation with branched-chain amino acids (BCAA; leucine, isoleucine, and valine) has been suggested to improve protein malnutrition in patients with liver cirrhosis (12). Recent studies have revealed that BCAA is useful for both preventing progressive hepatic failure and improving event-free survival in patients with chronic liver diseases, such as liver cirrhosis, and these beneficial effects are associated with the improvement of insulin resistance by BCAA (13–15). In addition, oral supplemental treatment with BCAA can reduce the risk of hepatocellular carcinoma in cirrhotic patients who...
Translational Relevance

Obesity and related metabolic abnormalities, including insulin resistance and the activation of the insulin-like growth factor (IGF)/IGF-I receptor axis, are associated with colorectal cancer (CRC) development. Therefore, the prevention of CRC by targeting the dysregulation of energy homeostasis might be a promising strategy for obese people who are at increased risks of CRC. We believe that this study is novel and clinically relevant because this article is the first report indicating that supplementation with branched-chain amino acids (BCAA) effectively suppressed the development of azoxymethane-induced putative precursor lesions of colonic adenocarcinoma in C57BL/KsJ-db/db mice that are obese and developed diabetes mellitus. Our studies indicate that this suppressing effect of BCAA was associated with improvement of hyperlipidemia and hyperleptinemia. BCAA supplementation could also improve insulin sensitivity and exert a depressant effect on the IGF/IGF-IR axis. The current findings suggest the possibility of using BCAA as a chemopreventive agent for obesity-related malignancies.

Materials and Methods

Animals, chemicals, and diets. Four-week-old male homozygous db/db mice were obtained from Japan SLC, Inc. All mice were maintained at the Gifu University Life Science Research Center according to the Institutional Animal Care Guidelines. AOM was purchased from Sigma the Gifu University Life Science Research. The BCAA composition (2:1:1.2, leucine/isoleucine/valine) was set at the clinical dosage that is used for the treatment of hypoalbuminemia in patients with decompensated liver cirrhosis in Japan.

Experimental procedure. The animal experiment was approved by the Institutional Committee of Animal Experiments of Gifu University. A total of 54 male db/db mice were divided into 6 groups. At 5 wk of age, the mice in groups 1 to 3 were s.c. injected with AOM (15 mg/kg of body weight) weekly for 4 wk. As controls, the mice in groups 4 to 6 were given s.c. injections of saline. Groups 1 (12 mice) and 4 (6 mice) were fed a basal diet, corticoterpin-releasing factor (CRF)-1 (Oriental Yeast Co., Ltd.), throughout the experiment. Groups 3 (12 mice) and 6 (6 mice) were given a basal diet containing 3.0% BCAA (weight for weight) for 7 wk, starting 1 wk after the last injection of AOM. The BCAA concentration (3.0%) was determined by the previous study, which indicated the same intake to improve insulin resistance in C57BL/6J mice (24). The mice in groups 2 (12 mice) and 5 (6 mice) were given a basal diet containing 3.0% casein (weight for weight). The casein-fed groups were served as nitrogen content–matched controls for the BCAA-treated groups to eliminate the possibility that the nitrogen content itself affects the promotion or the prevention of colonic premalignant lesions. At the termination of the study (16 wk of age), the mice were sacrificed by CO₂ asphyxiation to analyze the number of colonic ACF and BCAC.

Counting the number of ACF and BCAC. The ACF and BCAC were determined according to the standard procedures described previously (20, 21, 25). ACF are defined as single or multiple crypts that have altered luminal openings, exhibit thickened epithelia, and are larger than adjacent normal crypts (22). BCAC, which have high frequency mutations in the β-catenin gene, show histologic dysplasia with a disruption of the cellular morphology and an accumulation of this protein (Fig. 1A; ref. 23). BCAC do not have a typical ACF-like appearance because the lesion is not recognized on the mucosal surface like ACF and is only identified in the histologic sections of en face preparations. Both of these lesions are utilized as biomarkers to evaluate a number of agents for their potential chemopreventive properties (26). After the colons were fixed flat in 10% buffered formalin for 24 h, the mucosal surface of the colons were stained with methylene blue (0.5% in distilled water), and then the number of ACF were counted under a light microscope. Thereafter, the distal parts (5 cm from the anus) of the colon were cut to count the number of BCAC. To identify BCAC intramucosal lesions, the distal part of the colon (mean area, 0.7 cm² per colon) was embedded in paraffin, and then a total of 20 serial sections (4-μm thick each) per colon were made by an en face preparation (20, 21, 25). For each case, 2 serial sections were used to analyze BCAC.

Histopathology and immunohistochemical analyses for β-catenin and PCNA. Three serial sections were made from paraffin-embedded tissue blocks. Two sections were subjected to H&E staining for histopathology and β-catenin immunohistochemistry to count the number of BCAC. The other section was used for the proliferating cell nuclear antigen (PCNA), a G₁-to-S phase marker, immunohistochemistry to estimate the cell proliferative activity in the colonic mucosa. Immunohistochemical analyses for β-catenin and PCNA were done with the labeled streptavidin-biotin method (LSAB kit; DAKO) as previously described (20, 21). Anti–β-catenin antibody (1:1,000 final dilution) was obtained from Transduction Laboratories (catalogue no. 610154). Anti-PCNA antibody (1:100 final dilution) was from Santa Cruz Biotechnology, Inc. (sc-7907). Negative control sections were immunostained without the primary antibody. PCNA-positive cells in the colonic mucosa, which seemed normal by H&E staining, were counted and expressed as a percentage of the total number of normal crypt cells. The PCNA labeling index (%) was determined by counting at least 200 crypt cells in each mouse (a total of 1,000 crypt cells per group). Two experienced pathologists (Y. Hirose and T. Tanaka) immunohistologically determined the BCAC and PCNA-positive cells by computer-based protein extraction and western blot analysis. Total proteins were extracted from the scraped mucosa from the remaining colon of the AOM-treated mice (groups 1 to 3), and equivalent amounts of proteins
(40 μg per lane) were examined by a western blot analysis with the use of the primary antibodies for IGF-IR, phosphorylated IGF-IR (p-IGF-IR), phosphorylated glycogen synthase kinase 3β (p-GSK-3β), Akt, phosphorylated Akt (p-Akt), cyclooxygenase-2 (COX-2), and glyceraldehyde-3-phosphate dehydrogenase as described previously (11, 27, 28). An antibody to glyceraldehyde-3-phosphate dehydrogenase served as a loading control. The intensities of the blots were quantified with the NIH Image software version 1.62. The intensities of the blots found at the CRF-fed mice in each antibody was set at 1, and the changes in expression were shown as the fold difference.

Table 1. Body, liver, kidney, and white adipose tissue weights of the experimental mice

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Treatment</th>
<th>Diet</th>
<th>No. of mice</th>
<th>Final body weight (g)</th>
<th>Body length (cm)</th>
<th>BMI</th>
<th>Absolute organ weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>White adipose tissue</td>
</tr>
<tr>
<td>1</td>
<td>AOM 15 mg/kg</td>
<td>CRF-1</td>
<td>12</td>
<td>49.7 ± 8.3**</td>
<td>9.25 ± 0.77</td>
<td>0.58 ± 0.05</td>
<td>2.64 ± 0.76</td>
</tr>
<tr>
<td>2</td>
<td>AOM 15 mg/kg</td>
<td>Casein</td>
<td>12</td>
<td>51.7 ± 4.8</td>
<td>9.43 ± 0.37</td>
<td>0.58 ± 0.02</td>
<td>2.75 ± 0.48</td>
</tr>
<tr>
<td>3</td>
<td>AOM 15 mg/kg</td>
<td>BCAA</td>
<td>12</td>
<td>50.3 ± 5.0</td>
<td>9.47 ± 0.25</td>
<td>0.56 ± 0.04</td>
<td>2.58 ± 0.64</td>
</tr>
<tr>
<td>4</td>
<td>Saline</td>
<td>CRF-1</td>
<td>6</td>
<td>58.1 ± 2.5</td>
<td>9.63 ± 0.22</td>
<td>0.63 ± 0.02</td>
<td>3.35 ± 0.72</td>
</tr>
<tr>
<td>5</td>
<td>Saline</td>
<td>Casein</td>
<td>6</td>
<td>58.0 ± 2.1</td>
<td>9.70 ± 0.18</td>
<td>0.62 ± 0.01</td>
<td>3.87 ± 1.04</td>
</tr>
<tr>
<td>6</td>
<td>Saline</td>
<td>BCAA</td>
<td>6</td>
<td>58.5 ± 2.5</td>
<td>9.63 ± 0.17</td>
<td>0.63 ± 0.01</td>
<td>3.83 ± 0.86</td>
</tr>
</tbody>
</table>

*Mean ± SD.
**Significantly different from group 4 (P < 0.05).
†Significantly different from group 5 (P < 0.05).
‡Significantly different from group 6 (P < 0.05).
Clinical chemistry. At sacrifice, blood samples were collected from the AOM-treated mice (groups 1-3) to measure the serum concentrations of insulin, leptin, triglyceride, total cholesterol, IGF-I, IGF-II, and BCAA. The serum triglyceride, total cholesterol, and BCAA levels were assayed as described previously (20, 29). The serum insulin, leptin, IGF-I, and IGF-II were determined by an enzyme immunoassay according to the manufacturer's protocol (R&D Systems).

Statistical analysis. The results were presented as the mean ± SD and were analyzed with the use of the GraphPad InStat software program version 3.05 (GraphPad Software) for Macintosh. Differences between groups were analyzed by one-way ANOVA or, as required, by two-way ANOVA. When ANOVA showed a statistically significant effect (P < 0.05), comparisons of each experimental group with the control group were then made with the use of the Tukey-Kramer multiple comparisons test. The differences were considered significant when the two-tailed P was <0.05.

Results

General observations. As shown in Table 1, the average body weights of groups 1 (CRF-1) and 3 (BCAA) in the AOM-injected mice at the termination of this experiment were smaller than those of the saline-injected groups 4 (casein; weight in the AOM-treated group 1 was also significantly lower compared with those in the saline-treated groups 5 (casein; groups 2 (casein) and 3 (BCAA) were significantly lower than those of the saline-injected groups 4 (CRF-1; P < 0.05) and 6 (BCAA; P < 0.05). The mean liver weights in the AOM-treated groups 2 (casein) and 3 (BCAA) were significantly lower than those in the saline-treated groups 5 (casein; P < 0.05) and 6 (BCAA; P < 0.05). Among CRF-1–fed mice, the mean kidney weight in the AOM-treated group 1 was also significantly lower than that of the saline-treated group 4 (P < 0.05). No significant difference was observed in the body length, body mass index, and mean white adipose tissue weight among the experimental mice. A histopathologic examination also revealed no alteration, thus suggesting the absence of toxicity of BCAA in the liver and kidney of the mice in groups 3 and 6 (data not shown).

Effects of BCAA supplementation on AOM-induced ACF and BCAC formation in db/db mice. Table 2 summarizes the total number of ACF and BCAC (Fig. 1) in the mice of all groups. ACF and BCAC developed in the colons of all the mice that received AOM (groups 1 to 3) but not in the colons of the mice that did not receive AOM (groups 4 to 6). Dietary supplementation with BCAA significantly decreased the number of total ACF compared with those of the CRF-1–fed (37% reduction; P < 0.001) and casein-supplemented groups (35% reduction; P < 0.001). Compared with the CRF-1–fed group, the administration of BCAA also significantly reduced the number of total BCAC (64% reduction; P < 0.05).

Effects of BCAA supplementation on the serum levels of BCAA in AOM-treated db/db mice. Because the colonic premalignant lesions developed only in the AOM-injected mice (Table 2), the following experiments were done among the mice that received AOM (groups 1 to 3). BCAA supplementation caused a significant increase in the serum concentrations of total BCAA (valine, isoleucine, and leucine; 1736 ± 179 nmol/mL) compared with the CRF-1–fed (882 ± 160 nmol/mL; P < 0.001) and casein-supplemented groups (853 ± 51 nmol/mL; P < 0.001). These findings suggest that supplementation with 3.0% BCAA is sufficient to raise the serum concentration of BCAA.

Effects of BCAA supplementation on the serum levels of total cholesterol, triglyceride, and leptin in AOM-treated db/db mice. As shown in Table 3, the serum levels of total cholesterol in the BCAA-supplemented mice were significantly lower than

### Table 2. Effects of BCAA on AOM-induced ACF and BCAC formation in the experimental mice

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Treatment</th>
<th>Diet</th>
<th>No. of mice</th>
<th>Length of colon (cm)</th>
<th>Total no. of ACFs per colon</th>
<th>Total no. of BCACs/cm²</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AOM 15 mg/kg</td>
<td>CRF-1</td>
<td>12</td>
<td>12.4 ± 1.4*</td>
<td>85.9 ± 8.1</td>
<td>11.7 ± 8.4</td>
</tr>
<tr>
<td>2</td>
<td>AOM 15 mg/kg</td>
<td>Casein</td>
<td>12</td>
<td>12.5 ± 0.5</td>
<td>83.4 ± 11.2</td>
<td>8.3 ± 3.9</td>
</tr>
<tr>
<td>3</td>
<td>AOM 15 mg/kg</td>
<td>BCAA</td>
<td>12</td>
<td>12.0 ± 0.7</td>
<td>54.5 ± 8.6 ± 1.4</td>
<td>4.2 ± 6.7 ± 1.4</td>
</tr>
<tr>
<td>4</td>
<td>Saline</td>
<td>CRF-1</td>
<td>6</td>
<td>12.5 ± 1.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>Saline</td>
<td>Casein</td>
<td>6</td>
<td>11.5 ± 0.7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>Saline</td>
<td>BCAA</td>
<td>6</td>
<td>11.3 ± 0.5</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Mean ± SD.

1 Significantly different from group 1 (P < 0.001).

2 Significantly different from group 2 (P < 0.001).

3 Significantly different from group 1 (P < 0.05).

### Table 3. Serum levels of total cholesterol, triglyceride, and leptin in AOM-treated db/db mice

<table>
<thead>
<tr>
<th>Group no.</th>
<th>Treatment</th>
<th>Diet</th>
<th>No. of mice</th>
<th>Total cholesterol (mg/dL)</th>
<th>Triglyceride (mg/dL)</th>
<th>Leptin (ng/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AOM 15 mg/kg</td>
<td>CRF-1</td>
<td>12</td>
<td>185 ± 34*</td>
<td>244 ± 49</td>
<td>117 ± 18</td>
</tr>
<tr>
<td>2</td>
<td>AOM 15 mg/kg</td>
<td>Casein</td>
<td>12</td>
<td>186 ± 40</td>
<td>229 ± 40</td>
<td>133 ± 32</td>
</tr>
<tr>
<td>3</td>
<td>AOM 15 mg/kg</td>
<td>BCAA</td>
<td>12</td>
<td>141 ± 48 ± 1.4</td>
<td>187 ± 48 ± 1.4</td>
<td>99 ± 23 ± 1.4</td>
</tr>
</tbody>
</table>

*Mean ± SD.

1 Significantly different from group 1 (P < 0.05).

2 Significantly different from group 2 (P < 0.05).

3 Significantly different from group 2 (P < 0.01).
those in the CRF-1–fed (P < 0.05) and casein-supplemented mice (P < 0.05). The mice supplemented with BCAA showed a significant decrease in the serum levels of triglyceride compared with the CRF-1 fed (P < 0.05). The serum leptin level of group 3 (BCAA) was also significantly lower than that of group 2 (casein; P < 0.01).

**Effects of BCAA supplementation on the serum levels of insulin, IGF-I, and IGF-II in AOM-treated db/db mice.** Supplementation with BCAA caused a significant decrease in the serum levels of insulin (Fig. 2A) compared with the CRF-1–fed (P < 0.01) and casein-supplemented mice (P < 0.01). Similarly, there was a significant decrease in the serum levels of both IGF-I (Fig. 2B) and IGF-II (Fig. 2C) in BCAA-supplemented mice compared with the CRF-1–fed (P < 0.001 for each comparison) and casein-supplemented mice (P < 0.001 and P < 0.01, respectively).

**Effects of BCAA supplementation on the expression levels of IGF-IR, p-IGF-IR, p-GSK-3β, Akt, p-Akt, and COX-2 proteins, on cell proliferative activity in the colonic mucosa of AOM-treated db/db mice.** Hyperinsulinemia and abnormal activation of the IGF/IGF-IR axis play a critical role in obesity-related CRC development (3, 6–10). Therefore, the effects of BCAA on the levels of IGF-IR and the phosphorylated (i.e., activated) form of IGF-IR proteins, and cell proliferation were examined in the colonic mucosa of AOM-treated mice. As shown in Fig. 2D, western blot analyses showed that BCAA supplementation caused a decrease in the levels of IGF-IR (P < 0.001 for each comparison) and p-IGF-1R (P < 0.001 for each comparison) proteins compared with the CRF-1–fed and casein-supplemented mice. Supplementation with BCAA also decreased the expression levels of the phosphorylated (i.e., inactivated) form of GSK-3β (P < 0.01 for each comparison), the phosphorylated (i.e., activated) form of Akt (P < 0.001 for each comparison), and COX-2 (P < 0.01 for each comparison) proteins compared with the control groups. The finding that BCAA supplementation inhibited the phosphorylation of Akt is considered to be significant because the activation of this protein is one of the critical targets in the constitutive activation of the IGF/IGF-IR axis in colorectal carcinogenesis (30).

In addition, as shown in Fig. 3, the PCNA labeling index of nonlesional crypts in the BCAA-supplemented mice was significantly smaller than that of the CRF-1–fed and casein-supplemented mice (P < 0.001 for each comparison), thus indicating that BCAA supplementation significantly inhibits cell proliferation in the colonic mucosa of the AOM-treated db/db mice.

**Discussion**

The present study clearly indicated that dietary supplementation with BCAA effectively suppressed the development of putative precursor lesions, ACF and BCAC (Fig. 1), for CRC...
(Table 2) by improving hyperlipidemia and hyperleptinemia in \( db/db \) mice (Table 3). The suppressive effect of BCAA in the early phase of obesity-related colorectal carcinogenesis was also associated, most likely, with the improvement of hyperinsulinemia (Fig. 2A) and the inhibition of cell proliferation on the colonic mucosa of experimental mice (Fig. 3). BCAA supplementation has also been reported to significantly decrease the incidence of hepatocellular carcinoma in patients with chronic liver disease if they had a body mass index score \( \geq 25 \), and this effect might be associated with improvement of insulin resistance \((15, 16, 31)\). Thus, BCAA might effectively prevent cancer development, at least in several organs, in obese subjects who are considered to have insulin resistance syndrome \((3)\).

How can BCAA exert chemopreventive effects on obesity-related colorectal carcinogenesis? As described above, insulin resistance might be a critical target of BCAA in this beneficial effect because insulin has oncogenic properties on CRC cells. For instance, insulin stimulates the proliferation of CRC cells and promotes colorectal tumor growth in animal models \((6–8)\). These reports, therefore, suggest that BCAA inhibits the development of colonic premalignant lesions (Table 2) and excessive cell proliferation in the colonic mucosa of AOM-injected \( db/db \) mice (Fig. 3) by improving insulin resistance (Fig. 2A). Recent studies by others have indicated that BCAA improves glucose tolerance by modulating insulin-independent glucose uptake into skeletal muscle in rodent models \((32, 33)\). An improvement of insulin resistance and glucose tolerance by BCAA has also been shown by certain clinical trials \((15, 31)\).

In addition, it is widely accepted that insulin resistance causes alterations in the IGF/IGF-IR axis, which may be closely associated with the development of CRC \((9, 10, 30)\). For instance, the IGF-IR protein is overexpressed in BCAC compared with the surrounding normal cryptal cells \((11)\). Therefore, the IGF/IGF-IR system is regarded as one of the effective targets with respect to the prevention of CRC \((11)\). Our observations described herein comprise the first report showing that BCAA decreases the serum levels of IGF-I and IGF-II \((Fig. 2B and C)\), thereby inhibiting the expression and activation of IGF-IR on the colonic mucosa of AOM-treated \( db/db \) mice \((Fig. 2D)\). Our findings suggest that not only the improvement of insulin resistance but the inhibition of IGF/IGF-IR activation by BCAA plays a critical role in suppressing obesity-related and diabetes mellitus–related colorectal carcinogenesis.

The present study revealed that BCAA supplementation in the diet prevents the development of BCAC (Table 2), which is characterized by abundant \( \beta \)-catenin protein expression \((23)\) and also accumulates the IGF-IR protein \((11)\) while decreasing the expression levels of p-Akt and p-GSK-3\(\beta\) proteins on the colonic mucosa of AOM-treated \( db/db \) mice \((Fig. 2D)\). Recent \textit{in vitro} studies have indicated that insulin and the IGF/IGF-IR axis stabilize and activate the Wnt/\(\beta\)-catenin pathway, which is involved in the development of CRC \((34, 35)\). GSK-3\(\beta\), which can be phosphorylated by phosphatidylinositol 3-kinase/Akt via insulin or IGF treatment, is considered to be a key kinase for CRC development because the inactivation of GSK-3\(\beta\) leads to the dissociation of the adenomatous polyposis coli/axin/\(\beta\)-catenin complex and cytosolic \(\beta\)-catenin accumulation \((36)\).
Free accumulated β-catenin translocates into the nucleus and forms a complex with the transcription factor T cell factor, thereby activating the transcription of target genes, including cyclin D1 and c-Myc, and thus contributing to abnormal proliferation and tumor progression (37, 38). Therefore, supplementation with BCAA, which targets insulin-associated and IGF-associated β-catenin accumulation by decreasing the levels of p-Akt and p-GSK-3β proteins (Fig. 2D), might be an effective strategy to prevent the development of CRC.

In addition to the beneficial effects mentioned above, BCAA has other physiologic activities that might be useful to prevent the development of CRC. For instance, supplementation with BCAA is capable of reducing the production of oxidative stress and microinflammation in patients with liver cirrhosis, which possibly leads to a decrease in the occurrence of hepatocellular carcinoma (39). In the current study, BCAA caused a decrease in the expression of the COX-2 protein in the colonic mucosa of AOM-treated db/db mice (Fig. 2D). COX-2 is one of the main mediators in the inflammatory signaling pathway and is certainly involved in CRC development; therefore, it might be a critical target for CRC chemoprevention (40). This effect might be explained by the inhibitory effect of BCAA on the IGF/IGF-IR axis because the activation of this axis mediates COX-2 expression (41, 42). Additional studies are required to clarify the direct effects of BCAA on inflammation and their relevance to the antitumor effects of this agent.

In summary, the prevention of CRC by targeting the dysregulation of energy homeostasis, especially insulin resistance and the activation of the IGF/IGF-IR axis, might be a promising strategy for obese people who are at an increased risk of CRC. BCAA seems to be a potentially effective and critical candidate for this purpose because this agent can improve insulin resistance while also exerting a depressant effect on the IGF/IGF-IR axis. The current findings, as well as those from a previous report (11), also suggest the possibility of using specific agents that target insulin resistance as chemopreventive agents for other obesity-related and diabetes mellitus–related malignancies. Therefore, insulin resistance–improving agents, including BCAA, are worthy of being further investigated as candidates for novel chemopreventive agents that may find a potential role in the society today, in which excessive body weight has been found to be associated with the risk of various types of human epithelial malignancies (43, 44).

References

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Yukari Nomura for her excellent technical assistance.
Supplementation with Branched-chain Amino Acids Inhibits Azoxy methane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice

Masahito Shimizu, Yohei Shirakami, Junpei Iwasa, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/15/9/3068

Cited articles
This article cites 43 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/15/9/3068.full.html#ref-list-1

Citing articles
This article has been cited by 10 HighWire-hosted articles. Access the articles at:
/content/15/9/3068.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.